Tag: #Global Trends

Tessera Therapeutics, a genetic medicine firm backed by Flagship Pioneering, has disclosed plans to lay off 90 employees across several... Read more

Ollin Biosciences has reported compelling data from its Phase 1b "Jade" study, highlighting the superior performance of its bispecific antibody,... Read more

Pharmaceutical giant GSK has announced successful outcomes from its Phase III B-Well 1 and B-Well 2 clinical trials, establishing a... Read more

Aktis Oncology has set a high bar for the 2026 biotech financial calendar by raising $318 million in its initial... Read more

New data from the Phase 3b Together-PsA clinical trial indicates that the concurrent administration of ixekizumab (an IL-17A antagonist) and... Read more

Economic experts are offering mixed forecasts regarding Nestlé's potential losses following its global baby formula recall. According to analyses from... Read more

Pharmaceutical giant Eli Lilly has entered into a new research and licensing agreement with Nimbus Therapeutics. The partnership aims to... Read more

On January 8, 2026, the U.S. Food and Drug Administration (FDA) granted approval for a new 2-gram (g) formulation of... Read more

New data from the phase 3 Herizon-Gea-01 clinical trial signals a potential paradigm shift in the first-line treatment of HER2-positive... Read more